Alpelisib discontinuation rates in people with advanced HR-positive, HER2-negative breast cancer can be reduced with the use of a detailed adverse event management plan focusing on the most commonly occurring events

Phase III study data show no benefit of histology-tailored neoadjuvant chemotherapy over anthracycline plus ifosfamide in patients with localised high-risk soft tissue sarcoma of an extremity or the trunk wall

On-target adverse events associated with TRK inhibitor therapy may include weight gain and dizziness

Nivolumab achieved comparable overall survival to bevacizumab among glioblastoma patients who had previously been treated with radiotherapy and temozolomide

Pembrolizumab, trastuzumab and chemotherapy might help prevent disease progression in patients with HER2-positive metastatic gastric, oesophageal or gastro-oesophageal junction cancer

Elderly or frail patients with EGFR mutation-positive non-small-cell lung cancer could benefit from treatment with low-dose erlotinib

Second-line camrelizumab significantly improves the outcome of Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma compared with chemotherapy

 Immune checkpoint inhibitor use in patients with pretreated microsatellite instability-high tumours shows activity independent of tumour type